Spotlight Therapeutics is a venture funded early-stage biotechnology company with a mission to develop a new class of therapeutics by enabling direct in vivo gene editing.
Founded by Alex Marson (UCSF), Jacob Corn (UC Berkeley), and Patrick Hsu (Salk Institute) in December of 2017, Spotlight is building its core technology platform to achieve precise in vivo gene editing in targeted cell populations.
With a therapeutic focus centered on oncology, our engineered nucleases edit the genes in targeted disease organs thereby inactivating or altering the gene product.
We are hiring rapidly to build out our cutting-edge research and development team. This team is responsible for preclinical development ranging from protein engineering, gene editing to immuno-oncology and in vivo safety studies. Join us and work on the next generation of gene editing therapeutics in a fast-paced and exciting environment.